Holen Sie sich die Stockscreener-App
0.7163
2.43%
0.017
Handel nachbörslich:
.72
0.0037
+0.52%
Schlusskurs vom Vortag:
$0.6993
Offen:
$0.71
24-Stunden-Volumen:
34,522
Relative Volume:
0.21
Marktkapitalisierung:
$12.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.53M
KGV:
-0.1957
EPS:
-3.66
Netto-Cashflow:
$-39.93M
1W Leistung:
-8.05%
1M Leistung:
-36.04%
6M Leistung:
-41.76%
1J Leistung:
-53.79%
1-Tages-Spanne:
$0.7001
$0.7198
1-Wochen-Bereich:
$0.66
$0.7957
52-Wochen-Spanne:
$0.66
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
Firmenname
Unity Biotechnology Inc
Sektor
Branche
Telefon
(650) 416-1192
Adresse
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie UBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
0.7163 | 12.70M | 0 | -52.53M | -39.93M | -3.66 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-16 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-16 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-01-04 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-11-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-06-28 | Hochstufung | Citigroup | Sell → Buy |
| 2021-06-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-16 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-08-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Eingeleitet | Mizuho | Buy |
| 2018-05-29 | Eingeleitet | Citigroup | Buy |
| 2018-05-29 | Eingeleitet | Goldman | Neutral |
| 2018-05-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Unity Biotechnology Inc Aktie (UBX) Neueste Nachrichten
HC Wainwright Issues Optimistic Forecast for UBX Earnings - Defense World
Unity Biotechnology stock hits 52-week low at $0.66 - Investing.com
Unity Biotechnology stock hits 52-week low at $0.66 By Investing.com - Investing.com India
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
HC Wainwright & Co. Downgrades Unity Biotechnology (LSE:0YC0) - Nasdaq
Unity Biotechnology (NASDAQ:UBX) Receives Neutral Rating from HC Wainwright - Defense World
Unity Biotech stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Nigeria
This United States Steel Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Unity Biotechnology (UBX) Downgraded Amid Strategic Shifts | UBX Stock News - GuruFocus
HC Wainwright Downgrades Unity Biotechnology to Neutral From Buy, Adjusts Price Target to $2 From $4 - marketscreener.com
Unity Biotechnology (UBX) Downgrade: HC Wainwright & Co. Cuts Pr - GuruFocus
Unity Biotechnology (UBX) Downgrade: HC Wainwright & Co. Cuts Price Target | UBX Stock News - GuruFocus
Biotech company once valued at $700 million slashes entire workforce - MSN
Unity Biotechnology (NASDAQ:UBX) Rating Lowered to “Neutral” at Mizuho - Defense World
Mizuho cuts Unity Biotech stock rating, slashes price target to $1 - Investing.com Nigeria
Mizuho Downgrades Unity Biotechnology to Neutral From Outperform After Diabetic Edema Treatment Misses Primary Endpoint, Cuts Price Target to $1 From $6 - marketscreener.com
Unity Biotechnology (UBX) Downgraded Amid Trials and Strategic N - GuruFocus
Unity Biotechnology (UBX) to Release Earnings on Tuesday - Defense World
Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce - MSN
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Renaissance Technologies LLC Sells 16,759 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX) - Defense World
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Bay Area biotech company lays off every single worker, including CEO - SFGATE
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
UNITY Biotechnology (UBX) Reports Promising 36-Week Results from ASPIRE Trial | UBX Stock News - GuruFocus
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study - TipRanks
UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force - marketscreener.com
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates - The Manila Times
UNITY Biotechnology Announces Complete 36-Week Results from - GlobeNewswire
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of - Bluefield Daily Telegraph
UNITY's New DME Treatment Rivals Aflibercept in Phase 2b Trial, Company Explores Strategic Options - Stock Titan
UNITY Biotechnology to Present 36-Week Data from ASPIRE Phase 2B Study at ARVO 2025 Annual Meeting - Nasdaq
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting - The Manila Times
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
Chardan Capital Brokers Decrease Earnings Estimates for UBX - Defense World
Form 8-KCurrent report - ADVFN
HC Wainwright Issues Positive Outlook for UBX Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Chardan Capital Reaffirms “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Unity Biotechnology Reports Q1 2025 Financials and Study Updates - TipRanks
H.C. Wainwright maintains $4 target on Unity Biotech stock - Investing.com Australia
Unity Biotechnology (UBX) Reports $16.9M in Cash, Prepares for F - GuruFocus
H.C. Wainwright maintains $4 target on Unity Biotech stock By Investing.com - Investing.com Nigeria
UNITY Biotechnology (UBX) Shows Promise with Senolytic UBX1325 i - GuruFocus
UNITY Biotechnology Announces Publication in NEJM Evidence - GlobeNewswire
Revolutionary DME Drug Maintains Vision Improvement for 12 Months After Just One Dose, NEJM Study Shows - Stock Titan
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial R - GuruFocus
Finanzdaten der Unity Biotechnology Inc-Aktie (UBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):